Skip to main content
Erschienen in:

06.03.2024 | Hepatobiliary

Noninvasive identification of SOX9 status using radiomics signatures may help construct personalized treatment strategy in hepatocellular carcinoma

verfasst von: Feng Che, Yi Wei, Qing Xu, Qian Li, Tong Zhang, Li-Ye Wang, Man Li, Fang Yuan, Bin Song

Erschienen in: Abdominal Radiology | Ausgabe 9/2024

Einloggen, um Zugang zu erhalten

Abstract

Objectives

To develop and validate a radiomics-based model for predicting SOX9-positive hepatocellular carcinoma (HCC) using preoperative contrast-enhanced computed tomography (CT) images.

Methods

From January 2013 to April 2017, patients with histologically proven HCC who received systemic sorafenib treatment after curative resection were retrospectively enrolled. Radiomic features were extracted from portal venous phase CT images and selected to build a radiomics score using logistic regression analysis. The factors associated with SOX9 expression were selected and combined by univariate and multivariate analyses to establish clinico-liver imaging (CL) model and clinico-liver imaging-radiomics (CLR) model. Diagnostic performance was measured by area under curve (AUC). Overall survival (OS) and recurrence-free survival (RFS) rates were compared using Kaplan-Meier method.

Results

A total of 108 patients (training cohort: n = 80; validation cohort: n = 28) were enrolled. Multivariate analyses revealed that the albumin-bilirubin grade and tumor size were significant independent factors for predicting SOX9-positive HCCs and were included in the CL model. The CLR model integrating the radiomics score with albumin-bilirubin grade and tumor size showed better discriminative performance than the CL model with AUCs of 0.912 and 0.790 in the training and validation cohorts. Survival curves for RFS and OS showed that SOX9 expression was closely related to the prognosis of HCC patients. RFS and OS rates were significantly lower in patients with SOX9-positive than SOX9-negative (51.02% vs. 75.00% at 1-year RFS rates; 76.92% vs. 94.94% at 2-year OS rates).

Conclusion

Radiomics signatures may serve as noninvasive predictors for SOX9 status evaluation in patients with HCC and may aid in constructing individualized treatment strategies.

Graphical abstract

Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin 2021;71:209-249.PubMedCrossRef Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin 2021;71:209-249.PubMedCrossRef
2.
Zurück zum Zitat Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc J-F, de Oliveira AC, et al. Sorafenib in Advanced Hepatocellular Carcinoma. New England Journal of Medicine 2008;359:378-390.PubMedCrossRef Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc J-F, de Oliveira AC, et al. Sorafenib in Advanced Hepatocellular Carcinoma. New England Journal of Medicine 2008;359:378-390.PubMedCrossRef
3.
Zurück zum Zitat Cheng AL, Kang YK, Chen Z, Tsao CJ, Qin S, Kim JS, Luo R, et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol 2009;10:25-34.PubMedCrossRef Cheng AL, Kang YK, Chen Z, Tsao CJ, Qin S, Kim JS, Luo R, et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol 2009;10:25-34.PubMedCrossRef
4.
Zurück zum Zitat Huang Y, Zhang Z, Zhou Y, Yang J, Hu K, Wang Z. Should we apply sorafenib in hepatocellular carcinoma patients with microvascular invasion after curative hepatectomy? Onco Targets Ther 2019;12:541-548.PubMedPubMedCentralCrossRef Huang Y, Zhang Z, Zhou Y, Yang J, Hu K, Wang Z. Should we apply sorafenib in hepatocellular carcinoma patients with microvascular invasion after curative hepatectomy? Onco Targets Ther 2019;12:541-548.PubMedPubMedCentralCrossRef
5.
Zurück zum Zitat Dong W, Yan K, Yu H, Huo L, Xian Z, Zhao Y, Li J, et al. Prognostic Nomogram for Sorafenib Benefit in Hepatitis B Virus-Related Hepatocellular Carcinoma After Partial Hepatectomy. Front Oncol 2020;10:605057.PubMedCrossRef Dong W, Yan K, Yu H, Huo L, Xian Z, Zhao Y, Li J, et al. Prognostic Nomogram for Sorafenib Benefit in Hepatitis B Virus-Related Hepatocellular Carcinoma After Partial Hepatectomy. Front Oncol 2020;10:605057.PubMedCrossRef
6.
Zurück zum Zitat Yang J, Liang H, Hu K, Xiong Z, Cao M, Zhong Z, Yao Z, et al. The effects of several postoperative adjuvant therapies for hepatocellular carcinoma patients with microvascular invasion after curative resection: a systematic review and meta-analysis. Cancer Cell Int 2021;21:92.PubMedPubMedCentralCrossRef Yang J, Liang H, Hu K, Xiong Z, Cao M, Zhong Z, Yao Z, et al. The effects of several postoperative adjuvant therapies for hepatocellular carcinoma patients with microvascular invasion after curative resection: a systematic review and meta-analysis. Cancer Cell Int 2021;21:92.PubMedPubMedCentralCrossRef
7.
Zurück zum Zitat Zhang W, Zhao G, Wei K, Zhang Q, Ma W, Song T, Wu Q, et al. Adjuvant sorafenib reduced mortality and prolonged overall survival and post-recurrence survival in hepatocellular carcinoma patients after curative resection: a single-center experience. Biosci Trends 2014;8:333-338.PubMedCrossRef Zhang W, Zhao G, Wei K, Zhang Q, Ma W, Song T, Wu Q, et al. Adjuvant sorafenib reduced mortality and prolonged overall survival and post-recurrence survival in hepatocellular carcinoma patients after curative resection: a single-center experience. Biosci Trends 2014;8:333-338.PubMedCrossRef
8.
Zurück zum Zitat Xia F, Wu LL, Lau WY, Huan HB, Wen XD, Ma KS, Li XW, et al. Adjuvant sorafenib after heptectomy for Barcelona Clinic Liver Cancer-stage C hepatocellular carcinoma patients. World J Gastroenterol 2016;22:5384-5392.PubMedPubMedCentralCrossRef Xia F, Wu LL, Lau WY, Huan HB, Wen XD, Ma KS, Li XW, et al. Adjuvant sorafenib after heptectomy for Barcelona Clinic Liver Cancer-stage C hepatocellular carcinoma patients. World J Gastroenterol 2016;22:5384-5392.PubMedPubMedCentralCrossRef
9.
Zurück zum Zitat Li J, Hou Y, Cai XB, Liu B. Sorafenib after resection improves the outcome of BCLC stage C hepatocellular carcinoma. World J Gastroenterol 2016;22:4034-4040.PubMedPubMedCentralCrossRef Li J, Hou Y, Cai XB, Liu B. Sorafenib after resection improves the outcome of BCLC stage C hepatocellular carcinoma. World J Gastroenterol 2016;22:4034-4040.PubMedPubMedCentralCrossRef
10.
Zurück zum Zitat Panda M, Tripathi SK, Biswal BK. SOX9: An emerging driving factor from cancer progression to drug resistance. Biochim Biophys Acta Rev Cancer 2021;1875:188517.PubMedCrossRef Panda M, Tripathi SK, Biswal BK. SOX9: An emerging driving factor from cancer progression to drug resistance. Biochim Biophys Acta Rev Cancer 2021;1875:188517.PubMedCrossRef
11.
Zurück zum Zitat Guo W, Keckesova Z, Donaher JL, Shibue T, Tischler V, Reinhardt F, Itzkovitz S, et al. Slug and SOX9 cooperatively determine the mammary stem cell state. Cell 2012;148:1015-1028.PubMedPubMedCentralCrossRef Guo W, Keckesova Z, Donaher JL, Shibue T, Tischler V, Reinhardt F, Itzkovitz S, et al. Slug and SOX9 cooperatively determine the mammary stem cell state. Cell 2012;148:1015-1028.PubMedPubMedCentralCrossRef
12.
Zurück zum Zitat Kadaja M, Keyes BE, Lin M, Pasolli HA, Genander M, Polak L, Stokes N, et al. SOX9: a stem cell transcriptional regulator of secreted niche signaling factors. Genes Dev 2014;28:328-341.PubMedPubMedCentralCrossRef Kadaja M, Keyes BE, Lin M, Pasolli HA, Genander M, Polak L, Stokes N, et al. SOX9: a stem cell transcriptional regulator of secreted niche signaling factors. Genes Dev 2014;28:328-341.PubMedPubMedCentralCrossRef
13.
Zurück zum Zitat Guo X, Xiong L, Sun T, Peng R, Zou L, Zhu H, Zhang J, et al. Expression features of SOX9 associate with tumor progression and poor prognosis of hepatocellular carcinoma. Diagn Pathol 2012;7:44.PubMedPubMedCentralCrossRef Guo X, Xiong L, Sun T, Peng R, Zou L, Zhu H, Zhang J, et al. Expression features of SOX9 associate with tumor progression and poor prognosis of hepatocellular carcinoma. Diagn Pathol 2012;7:44.PubMedPubMedCentralCrossRef
14.
Zurück zum Zitat Liu C, Liu L, Chen X, Cheng J, Zhang H, Shen J, Shan J, et al. SOX9 regulates self-renewal and tumorigenicity by promoting symmetrical cell division of cancer stem cells in hepatocellular carcinoma. Hepatology 2016;64:117-129.PubMedCrossRef Liu C, Liu L, Chen X, Cheng J, Zhang H, Shen J, Shan J, et al. SOX9 regulates self-renewal and tumorigenicity by promoting symmetrical cell division of cancer stem cells in hepatocellular carcinoma. Hepatology 2016;64:117-129.PubMedCrossRef
15.
Zurück zum Zitat Leung CO, Mak WN, Kai AK, Chan KS, Lee TK, Ng IO, Lo RC. SOX9 confers stemness properties in hepatocellular carcinoma through Frizzled-7 mediated Wnt/β-catenin signaling. Oncotarget 2016;7:29371-29386.PubMedPubMedCentralCrossRef Leung CO, Mak WN, Kai AK, Chan KS, Lee TK, Ng IO, Lo RC. SOX9 confers stemness properties in hepatocellular carcinoma through Frizzled-7 mediated Wnt/β-catenin signaling. Oncotarget 2016;7:29371-29386.PubMedPubMedCentralCrossRef
16.
Zurück zum Zitat Wang M, Wang Z, Zhi X, Ding W, Xiong J, Tao T, Yang Y, et al. SOX9 enhances sorafenib resistance through upregulating ABCG2 expression in hepatocellular carcinoma. Biomed Pharmacother 2020;129:110315.PubMedCrossRef Wang M, Wang Z, Zhi X, Ding W, Xiong J, Tao T, Yang Y, et al. SOX9 enhances sorafenib resistance through upregulating ABCG2 expression in hepatocellular carcinoma. Biomed Pharmacother 2020;129:110315.PubMedCrossRef
17.
Zurück zum Zitat Aerts HJ, Velazquez ER, Leijenaar RT, Parmar C, Grossmann P, Carvalho S, Bussink J, et al. Decoding tumour phenotype by noninvasive imaging using a quantitative radiomics approach. Nat Commun 2014;5:4006.PubMedCrossRef Aerts HJ, Velazquez ER, Leijenaar RT, Parmar C, Grossmann P, Carvalho S, Bussink J, et al. Decoding tumour phenotype by noninvasive imaging using a quantitative radiomics approach. Nat Commun 2014;5:4006.PubMedCrossRef
18.
Zurück zum Zitat Gillies RJ, Kinahan PE, Hricak H. Radiomics: Images Are More than Pictures, They Are Data. Radiology 2016;278:563-577.PubMed Gillies RJ, Kinahan PE, Hricak H. Radiomics: Images Are More than Pictures, They Are Data. Radiology 2016;278:563-577.PubMed
19.
Zurück zum Zitat Lambin P, Rios-Velazquez E, Leijenaar R, Carvalho S, van Stiphout RG, Granton P, Zegers CM, et al. Radiomics: extracting more information from medical images using advanced feature analysis. Eur J Cancer 2012;48:441-446.PubMedPubMedCentralCrossRef Lambin P, Rios-Velazquez E, Leijenaar R, Carvalho S, van Stiphout RG, Granton P, Zegers CM, et al. Radiomics: extracting more information from medical images using advanced feature analysis. Eur J Cancer 2012;48:441-446.PubMedPubMedCentralCrossRef
20.
Zurück zum Zitat Segal E, Sirlin CB, Ooi C, Adler AS, Gollub J, Chen X, Chan BK, et al. Decoding global gene expression programs in liver cancer by noninvasive imaging. Nat Biotechnol 2007;25:675-680.PubMedCrossRef Segal E, Sirlin CB, Ooi C, Adler AS, Gollub J, Chen X, Chan BK, et al. Decoding global gene expression programs in liver cancer by noninvasive imaging. Nat Biotechnol 2007;25:675-680.PubMedCrossRef
21.
Zurück zum Zitat Rutman AM, Kuo MD. Radiogenomics: creating a link between molecular diagnostics and diagnostic imaging. Eur J Radiol 2009;70:232-241.PubMedCrossRef Rutman AM, Kuo MD. Radiogenomics: creating a link between molecular diagnostics and diagnostic imaging. Eur J Radiol 2009;70:232-241.PubMedCrossRef
22.
Zurück zum Zitat Ma X, Wei J, Gu D, Zhu Y, Feng B, Liang M, Wang S, et al. Preoperative radiomics nomogram for microvascular invasion prediction in hepatocellular carcinoma using contrast-enhanced CT. Eur Radiol 2019;29:3595-3605.PubMedCrossRef Ma X, Wei J, Gu D, Zhu Y, Feng B, Liang M, Wang S, et al. Preoperative radiomics nomogram for microvascular invasion prediction in hepatocellular carcinoma using contrast-enhanced CT. Eur Radiol 2019;29:3595-3605.PubMedCrossRef
23.
Zurück zum Zitat Chen S, Feng S, Wei J, Liu F, Li B, Li X, Hou Y, et al. Pretreatment prediction of immunoscore in hepatocellular cancer: a radiomics-based clinical model based on Gd-EOB-DTPA-enhanced MRI imaging. Eur Radiol 2019;29:4177-4187.PubMedCrossRef Chen S, Feng S, Wei J, Liu F, Li B, Li X, Hou Y, et al. Pretreatment prediction of immunoscore in hepatocellular cancer: a radiomics-based clinical model based on Gd-EOB-DTPA-enhanced MRI imaging. Eur Radiol 2019;29:4177-4187.PubMedCrossRef
24.
Zurück zum Zitat EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma. J Hepatol 2018;69:182-236.CrossRef EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma. J Hepatol 2018;69:182-236.CrossRef
25.
Zurück zum Zitat Heimbach JK, Kulik LM, Finn RS, Sirlin CB, Abecassis MM, Roberts LR, Zhu AX, et al. AASLD guidelines for the treatment of hepatocellular carcinoma. Hepatology 2018;67:358-380.PubMedCrossRef Heimbach JK, Kulik LM, Finn RS, Sirlin CB, Abecassis MM, Roberts LR, Zhu AX, et al. AASLD guidelines for the treatment of hepatocellular carcinoma. Hepatology 2018;67:358-380.PubMedCrossRef
26.
Zurück zum Zitat Xie DY, Ren ZG, Zhou J, Fan J, Gao Q. 2019 Chinese clinical guidelines for the management of hepatocellular carcinoma: updates and insights. Hepatobiliary Surg Nutr 2020;9:452-463.PubMedPubMedCentralCrossRef Xie DY, Ren ZG, Zhou J, Fan J, Gao Q. 2019 Chinese clinical guidelines for the management of hepatocellular carcinoma: updates and insights. Hepatobiliary Surg Nutr 2020;9:452-463.PubMedPubMedCentralCrossRef
27.
Zurück zum Zitat Bennett AV, Dueck AC, Mitchell SA, Mendoza TR, Reeve BB, Atkinson TM, Castro KM, et al. Mode equivalence and acceptability of tablet computer-, interactive voice response system-, and paper-based administration of the U.S. National Cancer Institute's Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE). Health Qual Life Outcomes 2016;14:24. Bennett AV, Dueck AC, Mitchell SA, Mendoza TR, Reeve BB, Atkinson TM, Castro KM, et al. Mode equivalence and acceptability of tablet computer-, interactive voice response system-, and paper-based administration of the U.S. National Cancer Institute's Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE). Health Qual Life Outcomes 2016;14:24.
28.
Zurück zum Zitat Palmer DH. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008;359:2498; author reply 2498-2499. Palmer DH. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008;359:2498; author reply 2498-2499.
29.
Zurück zum Zitat Wang W, Gu D, Wei J, Ding Y, Yang L, Zhu K, Luo R, et al. A radiomics-based biomarker for cytokeratin 19 status of hepatocellular carcinoma with gadoxetic acid-enhanced MRI. Eur Radiol 2020;30:3004-3014.PubMedCrossRef Wang W, Gu D, Wei J, Ding Y, Yang L, Zhu K, Luo R, et al. A radiomics-based biomarker for cytokeratin 19 status of hepatocellular carcinoma with gadoxetic acid-enhanced MRI. Eur Radiol 2020;30:3004-3014.PubMedCrossRef
30.
Zurück zum Zitat Sun R, Limkin EJ, Vakalopoulou M, Dercle L, Champiat S, Han SR, Verlingue L, et al. A radiomics approach to assess tumour-infiltrating CD8 cells and response to anti-PD-1 or anti-PD-L1 immunotherapy: an imaging biomarker, retrospective multicohort study. Lancet Oncol 2018;19:1180-1191.PubMedCrossRef Sun R, Limkin EJ, Vakalopoulou M, Dercle L, Champiat S, Han SR, Verlingue L, et al. A radiomics approach to assess tumour-infiltrating CD8 cells and response to anti-PD-1 or anti-PD-L1 immunotherapy: an imaging biomarker, retrospective multicohort study. Lancet Oncol 2018;19:1180-1191.PubMedCrossRef
31.
Zurück zum Zitat Gönczy P. Mechanisms of asymmetric cell division: flies and worms pave the way. Nat Rev Mol Cell Biol 2008;9:355-366.PubMedCrossRef Gönczy P. Mechanisms of asymmetric cell division: flies and worms pave the way. Nat Rev Mol Cell Biol 2008;9:355-366.PubMedCrossRef
32.
Zurück zum Zitat Wang W, Li Y, Li X, Liu B, Han S, Li X, Zhang B, et al. Circular RNA circ-FOXP1 induced by SOX9 promotes hepatocellular carcinoma progression via sponging miR-875-3p and miR-421. Biomed Pharmacother 2020;121:109517.PubMedCrossRef Wang W, Li Y, Li X, Liu B, Han S, Li X, Zhang B, et al. Circular RNA circ-FOXP1 induced by SOX9 promotes hepatocellular carcinoma progression via sponging miR-875-3p and miR-421. Biomed Pharmacother 2020;121:109517.PubMedCrossRef
33.
Zurück zum Zitat Johnson PJ, Berhane S, Kagebayashi C, Satomura S, Teng M, Reeves HL, O'Beirne J, et al. Assessment of liver function in patients with hepatocellular carcinoma: a new evidence-based approach-the ALBI grade. J Clin Oncol 2015;33:550-558.PubMedCrossRef Johnson PJ, Berhane S, Kagebayashi C, Satomura S, Teng M, Reeves HL, O'Beirne J, et al. Assessment of liver function in patients with hepatocellular carcinoma: a new evidence-based approach-the ALBI grade. J Clin Oncol 2015;33:550-558.PubMedCrossRef
34.
Zurück zum Zitat Kuo YH, Wang JH, Hung CH, Rau KM, Wu IP, Chen CH, Kee KM, et al. Albumin-Bilirubin grade predicts prognosis of HCC patients with sorafenib use. J Gastroenterol Hepatol 2017;32:1975-1981.PubMedCrossRef Kuo YH, Wang JH, Hung CH, Rau KM, Wu IP, Chen CH, Kee KM, et al. Albumin-Bilirubin grade predicts prognosis of HCC patients with sorafenib use. J Gastroenterol Hepatol 2017;32:1975-1981.PubMedCrossRef
35.
Zurück zum Zitat Abdel-Rahman O. Impact of baseline characteristics on outcomes of advanced HCC patients treated with sorafenib: a secondary analysis of a phase III study. J Cancer Res Clin Oncol 2018;144:901-908.PubMedCrossRef Abdel-Rahman O. Impact of baseline characteristics on outcomes of advanced HCC patients treated with sorafenib: a secondary analysis of a phase III study. J Cancer Res Clin Oncol 2018;144:901-908.PubMedCrossRef
36.
Zurück zum Zitat Wang C, Deng J, Deng H, Kang Z, Huang Z, Ding Z, Dong L, et al. A Novel SOX9/lncRNA H19 Axis Contributes to Hepatocyte Death and Liver Fibrosis. Toxicol Sci 2020;177:214-225.PubMedCrossRef Wang C, Deng J, Deng H, Kang Z, Huang Z, Ding Z, Dong L, et al. A Novel SOX9/lncRNA H19 Axis Contributes to Hepatocyte Death and Liver Fibrosis. Toxicol Sci 2020;177:214-225.PubMedCrossRef
37.
Zurück zum Zitat Español-Suñer R, Carpentier R, Van Hul N, Legry V, Achouri Y, Cordi S, Jacquemin P, et al. Liver progenitor cells yield functional hepatocytes in response to chronic liver injury in mice. Gastroenterology 2012;143:1564-1575.e1567.PubMedCrossRef Español-Suñer R, Carpentier R, Van Hul N, Legry V, Achouri Y, Cordi S, Jacquemin P, et al. Liver progenitor cells yield functional hepatocytes in response to chronic liver injury in mice. Gastroenterology 2012;143:1564-1575.e1567.PubMedCrossRef
38.
Zurück zum Zitat Pritchett J, Harvey E, Athwal V, Berry A, Rowe C, Oakley F, Moles A, et al. Osteopontin is a novel downstream target of SOX9 with diagnostic implications for progression of liver fibrosis in humans. Hepatology 2012;56:1108-1116.PubMedCrossRef Pritchett J, Harvey E, Athwal V, Berry A, Rowe C, Oakley F, Moles A, et al. Osteopontin is a novel downstream target of SOX9 with diagnostic implications for progression of liver fibrosis in humans. Hepatology 2012;56:1108-1116.PubMedCrossRef
39.
Zurück zum Zitat Toyoda H, Lai PB, O'Beirne J, Chong CC, Berhane S, Reeves H, Manas D, et al. Long-term impact of liver function on curative therapy for hepatocellular carcinoma: application of the ALBI grade. Br J Cancer 2016;114:744-750.PubMedPubMedCentralCrossRef Toyoda H, Lai PB, O'Beirne J, Chong CC, Berhane S, Reeves H, Manas D, et al. Long-term impact of liver function on curative therapy for hepatocellular carcinoma: application of the ALBI grade. Br J Cancer 2016;114:744-750.PubMedPubMedCentralCrossRef
40.
Zurück zum Zitat Tabrizian P, Jibara G, Shrager B, Schwartz M, Roayaie S. Recurrence of hepatocellular cancer after resection: patterns, treatments, and prognosis. Ann Surg 2015;261:947-955.PubMedCrossRef Tabrizian P, Jibara G, Shrager B, Schwartz M, Roayaie S. Recurrence of hepatocellular cancer after resection: patterns, treatments, and prognosis. Ann Surg 2015;261:947-955.PubMedCrossRef
41.
Zurück zum Zitat Kawai T, Yasuchika K, Ishii T, Miyauchi Y, Kojima H, Yamaoka R, Katayama H, et al. SOX9 is a novel cancer stem cell marker surrogated by osteopontin in human hepatocellular carcinoma. Sci Rep 2016;6:30489.PubMedPubMedCentralCrossRef Kawai T, Yasuchika K, Ishii T, Miyauchi Y, Kojima H, Yamaoka R, Katayama H, et al. SOX9 is a novel cancer stem cell marker surrogated by osteopontin in human hepatocellular carcinoma. Sci Rep 2016;6:30489.PubMedPubMedCentralCrossRef
42.
Zurück zum Zitat Richtig G, Aigelsreiter A, Schwarzenbacher D, Ress AL, Adiprasito JB, Stiegelbauer V, Hoefler G, et al. SOX9 is a proliferation and stem cell factor in hepatocellular carcinoma and possess widespread prognostic significance in different cancer types. PLoS One 2017;12:e0187814.PubMedPubMedCentralCrossRef Richtig G, Aigelsreiter A, Schwarzenbacher D, Ress AL, Adiprasito JB, Stiegelbauer V, Hoefler G, et al. SOX9 is a proliferation and stem cell factor in hepatocellular carcinoma and possess widespread prognostic significance in different cancer types. PLoS One 2017;12:e0187814.PubMedPubMedCentralCrossRef
Metadaten
Titel
Noninvasive identification of SOX9 status using radiomics signatures may help construct personalized treatment strategy in hepatocellular carcinoma
verfasst von
Feng Che
Yi Wei
Qing Xu
Qian Li
Tong Zhang
Li-Ye Wang
Man Li
Fang Yuan
Bin Song
Publikationsdatum
06.03.2024
Verlag
Springer US
Erschienen in
Abdominal Radiology / Ausgabe 9/2024
Print ISSN: 2366-004X
Elektronische ISSN: 2366-0058
DOI
https://doi.org/10.1007/s00261-024-04190-2

Neu im Fachgebiet Radiologie

Ab sofort gelten die neuen Verordnungsausnahmen für Lipidsenker

Freie Fahrt für Lipidsenker? Das nicht, doch mit niedrigerem Schwellenwert fürs Infarktrisiko und neuen Indikationen hat der G-BA die Verordnungs-Handbremse ein gutes Stück weit gelockert.

Abdominale CT bei Kindern: 40% mit Zufallsbefunden

Wird bei Kindern mit stumpfem Trauma eine CT des Bauchraums veranlasst, sind in rund 40% der Fälle Auffälligkeiten zu sehen, die nichts mit dem Trauma zu tun haben. Die allerwenigsten davon sind klinisch relevant.

Genügt die biparametrische MRT für die Prostatadiagnostik?

Die multiparametrische Magnetresonanztomografie hat einen festen Platz im Screening auf klinisch signifikante Prostatakarzinome. Ob auch ein biparametrisches Vorgehen ausreicht, ist in einer Metaanalyse untersucht worden.

Höhere Trefferquoten bei Brustkrebsscreening dank KI?

Künstliche Intelligenz unterstützt bei der Auswertung von Mammografie-Screenings und senkt somit den radiologischen Arbeitsaufwand. Wie wirken sich diese Technologien auf die Trefferquote und die Falsch-positiv-Rate aus? Das hat jetzt eine Studie aus Schweden untersucht.

Update Radiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.